
News and Publications
Publication Categories
7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors
7 Hills Pharma has successfully dosed the first patient in a Phase 1b/2a clinical trial of Alintegimod, a first-in-class integrin-targeted agonist aimed at overcoming aPD-1-resistant solid tumors. This novel approach enhances T cell activation and immune cell trafficking, offering new hope for patients with difficult-to-treat cancers. Supported by CPRIT and the National Cancer Institute, this trial marks a significant advancement in cancer immunotherapy.
7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma
7 Hills Pharma announces that 7HP349, its lead oral immunostimulant, has been granted FDA Fast Track designation for use in combination with a CTLA-4 inhibitor for the treatment of anti-PD-1-resistant metastatic melanoma. This designation offers an expedited path for the development of 7HP349 in overcoming immunotherapy resistance in melanoma and other cancers.